Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L03 IMMUNOSTIMULANTS
L03A IMMUNOSTIMULANTS
L03AX Other immunostimulants
L03AX22 Leniolisib
D11159 Leniolisib phosphate (JAN/USAN) <US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Leniolisib
D11159 Leniolisib phosphate (JAN/USAN)
Drug groups [BR:br08330]
Antineoplastic
DG03139 PI3K inhibitor
DG02927 Leniolisib
D11159 Leniolisib phosphate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02927 Leniolisib
D11159 Leniolisib phosphate
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Phosphotransferase
PIK3CD
D11159 Leniolisib phosphate (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11159
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11159
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11159
Drug groups [BR:br08330]
Antineoplastic
DG03139 PI3K inhibitor
DG02927 Leniolisib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02927 Leniolisib